海洋来源药物：癌症治疗和免疫信号转导的最新进展。

Marine-derived drugs: Recent advances in cancer therapy and immune signaling.

机构信息

The Key Laboratory of Innate Immune Biology of Fujian Province, Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Biomedical Research Center of South China, Key Laboratory of OptoElectronic Science and Technology for Medicine of the Ministry of Education, College of Life Sciences, Fujian Normal University, Fuzhou, 350117, China; Laboratory for Marine Biology and Biotechnology, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao, 266237, China; College of Chemistry and Materials Science, Fujian Normal University, Fuzhou, 350117, China.

出版信息

Biomed Pharmacother. 2021 Feb;134:111091. doi: 10.1016/j.biopha.2020.111091. Epub 2020 Dec 16.

DOI:10.1016/j.biopha.2020.111091

PMID:33341044

Abstract

The marine environment is an enormous source of marine-derived natural products (MNPs), and future investigation into anticancer drug discovery. Current progress in anticancer drugs offers a rise in isolation and clinical validation of numerous innovative developments and advances in anticancer therapy. However, only a limited number of FDA-approved marine-derived anticancer drugs are available due to several challenges and limitations highlighted here. The use of chitosan in developing marine-derived drugs is promising in the nanotech sector projected for a prolific anticancer drug delivery system (DDS). The cGAS-STING-mediated immune signaling pathway is crucial, which has not been significantly investigated in anticancer therapy and needs further attention. Additionally, a small range of anticancer mediators is currently involved in regulating various JAK/STAT signaling pathways, such as immunity, cell death, and tumor formation. This review addressed critical features associated with MNPs, origin, and development of anticancer drugs. Moreover, recent advances in the nanotech delivery of anticancer drugs and understanding into cancer immunity are detailed for improved human health.

摘要

海洋环境是海洋来源的天然产物（MNPs）的巨大来源，也是未来抗癌药物发现的研究方向。目前抗癌药物的进展为抗癌疗法的许多创新发展和进步提供了分离和临床验证的机会。然而，由于这里强调的几个挑战和局限性，只有少数几种经 FDA 批准的海洋来源的抗癌药物可用。壳聚糖在开发海洋来源药物方面具有广阔的前景，有望在纳米技术领域构建高效的抗癌药物输送系统（DDS）。cGAS-STING 介导的免疫信号通路在抗癌治疗中尚未得到充分研究，需要进一步关注。此外，目前只有一小部分抗癌介质参与调节各种 JAK/STAT 信号通路，如免疫、细胞死亡和肿瘤形成。本综述讨论了与 MNPs、起源和抗癌药物开发相关的关键特征。此外，还详细介绍了抗癌药物的纳米技术输送和癌症免疫方面的最新进展，以改善人类健康。